BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
GlobeNewswire
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more..